Cumberland Pharmaceuticals (CPIX) Non Operating Interest Expenses (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Non Operating Interest Expenses across 17 years of filings, most recently posting $724.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 53.72% year-over-year to $724.0; the TTM figure through Jun 2026 stood at $309204.0 (down 41.09% YoY), while the FY2025 annual figure was $495990.0, down 18.09% from the prior year.
• Non Operating Interest Expenses came in at $724.0 for Q2 2026 at Cumberland Pharmaceuticals, down from $85839.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $223261.0 in Q4 2024 to a low of $471.0 in Q2 2025.
• Average Non Operating Interest Expenses over 5 years is $129602.3, with a median of $131860.5 recorded in 2024.
• Year-over-year, Non Operating Interest Expenses surged 645.92% in 2022 and plunged 99.63% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $179456.0 in 2022, then retreated by 0.37% to $178792.0 in 2023, then grew by 24.87% to $223261.0 in 2024, then plunged by 49.41% to $112942.0 in 2025, then sank by 99.36% to $724.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $724.0 in Q2 2026, $85839.0 in Q1 2026, and $112942.0 in Q4 2025.